
IMRX
Healthcare · Biotechnology · $240.3M market cap
$3.71+0.04 (+1.1%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -15.9% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2026 | After the close | -0.29 | -0.37 | -27.6% |
| Aug 5, 2026 | Before the open | -0.26 | -0.27 | -3.8% |
| May 12, 2026 | Time not confirmed | -0.35 | -0.21 | +40.0% |
| Mar 6, 2026 | Before the open | -0.31 | -0.18 | +41.9% |
| Nov 12, 2025 | After the close | -0.39 | -0.38 | +2.6% |
| Aug 13, 2025 | After the close | -0.40 | -0.40 | 0.0% |
| May 5, 2025 | After the close | -0.58 | -0.42 | +27.6% |
| Mar 20, 2025 | Time not confirmed | -0.45 | -1.07 | -137.8% |
| Nov 13, 2024 | After the close | -0.55 | -0.49 | +10.9% |
| Aug 6, 2024 | After the close | -0.53 | -0.47 | +11.3% |
| May 7, 2024 | After the close | -0.50 | -0.49 | +2.0% |
| Mar 1, 2024 | Before the open | -0.47 | -0.52 | -10.6% |
| Nov 9, 2023 | After the close | -0.49 |
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical…
| -0.43 |
| +12.2% |
| Aug 3, 2023 | After the close | -0.53 | -0.43 | +18.9% |
| May 4, 2023 | After the close | -0.56 | -0.51 | +8.9% |
| Mar 6, 2023 | After the close | -0.58 | -0.50 | +13.8% |
| Nov 10, 2022 | Before the open | -0.48 | -0.49 | -2.1% |
| Aug 10, 2022 | After the close | -0.52 | -0.44 | +15.4% |
| May 10, 2022 | Before the open | -0.44 | -0.49 | -11.4% |
| Mar 10, 2022 | Before the open | -0.39 | -0.42 | -7.7% |
| Nov 9, 2021 | Before the open | -0.62 | -0.47 | +24.2% |
| Sep 9, 2021 | Before the open | -1.44 | -1.61 | -11.8% |
| Jun 2, 2021 | Time not confirmed | -1.25 | -1.26 | -0.8% |
| Mar 31, 2021 | Time not confirmed | 0.00 | -1.26 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.65 | — |